Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Electronic Pedigree Program On Track, FDA Says; PhRMA Skeptical

Executive Summary

FDA's plan to implement a prescription drug electronic pedigree system by 2007 is "overly optimistic," the Pharmaceutical Research & Manufacturers of America says in a May 12 "white paper.

You may also be interested in...



FDA Anticounterfeiting Policy: Pilot Programs Will Not Trigger Enforcement

FDA will participate in developing anticounterfeiting standards with interested parties, Senior Advisor for Medical & Health Policy Paul Rudolf, MD, said

FDA Anticounterfeit Carrot & Stick: Radio Frequency I.D., No Paper Pedigree

FDA's anticounterfeiting strategy advocates radio frequency identification in lieu of paper pedigrees to secure the drug supply chain

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel